A male patient in his early 40s...underwent lymph node puncture...and the disease was pathologically confirmed as LUAD...three RET rearrangements were identified: CCDC6-RET (C1:R12) (2.55%), CCDC6-RET (C2:R12) (3.89%), and RET-NRG3 (R11:N3) (0.83%)….The patient was administered pralsetinib....After 4 days, the physical condition of the patient had substantially improved, and the PS score after 1 week was 1. In July 2021, a follow-up CT showed that a partial response (PR) had been achieved (Figure 2). The patient’s disease has remained stable to date.